Rezafungin Clinical Use and Dosing Guidelines

FDA‑Approved Position and Class Context

• Rezafungin is the fourth echinocandin approved for candidemia and invasive candidiasis, joining caspofungin, micafungin, and anidulafungin. 1

Dosing Regimen and Pharmacokinetic Advantages

• Once‑weekly intravenous dosing (400 mg loading, then 200 mg weekly) differs from first‑generation echinocandins, which require daily administration. [2][3]

Dose Adjustments in Special Populations

• No dose adjustment is needed for patients weighing 34–154.5 kg. 2
• No dose adjustment is required for hepatic impairment up to Child‑Pugh class B or C. 1
• No dose adjustment is required for patients on hemodialysis. 3
• No dose adjustment is required based on sex or race. 1

Drug‑Drug Interaction Profile

• Rezafungin does not significantly affect cytochrome P450 enzymes (CYP1A2, CYP2C8, CYP3A). 1
• Rezafungin does not significantly affect major drug transporters (P‑gp, OATP, BCRP, OCT, MATE). 1

Safety and Adverse Event Profile

• Pneumonia was reported as a treatment‑emergent adverse event in ≥5 % of patients. 1
• Septic shock was reported as a treatment‑emergent adverse event in ≥5 % of patients. 2

Comparison with Guideline‑Recommended Echinocandins (IDSA 2016)

• Caspofungin: 70 mg loading dose, then 50 mg daily. [2][3]
• Micafungin: 100 mg daily. [2][3]
• Anidulafungin: 200 mg loading dose, then 100 mg daily. [2][3]

Distinct Therapeutic Identity

• Rezafungin is not interchangeable with conventional echinocandins because of its markedly longer half‑life and weekly dosing paradigm. 4

Indications Not Covered by Rezafungin

• Rezafungin is not approved for the treatment of invasive aspergillosis. 4

Populations Excluded from Clinical Trials

Recommended Treatment Duration

• Standard therapy is 2 weeks after documented clearance of Candida from the bloodstream and resolution of symptoms, corresponding to 2–4 weekly doses (minimum 2 doses, maximum 4 doses for uncomplicated cases). [2][3]